Meeder Asset Management Inc Neurocrine Biosciences Inc Transaction History

Meeder Asset Management Inc

$1.47 Billion
Q1 2025

A detailed history of Meeder Asset Management Inc transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Meeder Asset Management Inc holds 24 shares of NBIX stock, worth $2,994. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Previous 41 41.46%

Holding current value

$2,994

Previous $5,000 60.0%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 07, 2025	SELL	$107.22 - $153.29 $1,822 - $2,605	-17 Reduced 41.46%	24 $2,000
Q4 2024 Feb 12, 2025	BUY	$111.62 - $139.44 $111 - $139	1 Added 2.5%	41 $5,000
Q3 2024 Nov 07, 2024	SELL	$114.58 - $153.15 $916 - $1,225	-8 Reduced 16.67%	40 $4,000
Q1 2024 May 07, 2024	BUY	$130.4 - $143.74 $6,259 - $6,899	48 New	48 $6,000
Q1 2023 May 15, 2023	SELL	$94.11 - $123.02 $106,061 - $138,643	-1,127 Reduced 91.85%	100 $10,000
Q4 2022 Feb 14, 2023	SELL	$106.72 - $127.06 $341,397 - $406,464	-3,199 Reduced 72.28%	1,227 $146,000
Q3 2022 Nov 14, 2022	BUY	$92.03 - $107.81 $391,403 - $458,515	4,253 Added 2458.38%	4,426 $469,000
Q2 2022 Aug 08, 2022	SELL	$75.79 - $100.07 $2,425 - $3,202	-32 Reduced 15.61%	173 $17,000
Q1 2022 May 10, 2022	BUY	$72.45 - $94.81 $14,852 - $19,436	205 New	205 $19,000
Q4 2021 Feb 11, 2022	SELL	$79.65 - $106.22 $40,143 - $53,534	-504 Closed	0 $0
Q3 2021 Nov 08, 2021	BUY	$86.18 - $99.03 $35,678 - $40,998	414 Added 460.0%	504 $48,000
Q2 2021 Aug 09, 2021	SELL	$89.43 - $102.27 $448,402 - $512,781	-5,014 Reduced 98.24%	90 $9,000
Q1 2021 Apr 28, 2021	BUY	$87.57 - $119.4 $445,118 - $606,910	5,083 Added 24204.76%	5,104 $496,000
Q4 2020 Feb 09, 2021	SELL	$86.91 - $108.33 $737,778 - $919,613	-8,489 Reduced 99.75%	21 $2,000
Q3 2020 Nov 02, 2020	SELL	$96.16 - $135.15 $61,350 - $86,225	-638 Reduced 6.97%	8,510 $818,000
Q2 2020 Aug 11, 2020	SELL	$85.09 - $130.36 $85,090 - $130,360	-1,000 Reduced 9.85%	9,148 $1.12 Million
Q1 2020 May 15, 2020	BUY	$75.11 - $113.76 $308,401 - $467,098	4,106 Added 67.96%	10,148 $878,000
Q4 2019 Feb 13, 2020	BUY	$86.8 - $118.57 $98,084 - $133,984	1,130 Added 23.0%	6,042 $650,000
Q3 2019 Oct 17, 2019	BUY	$83.82 - $101.5 $410,969 - $497,654	4,903 Added 54477.78%	4,912 $441,000
Q2 2019 Aug 05, 2019	BUY	$72.24 - $91.27 $650 - $821	9 New	9 $1,000
Q1 2019 Apr 16, 2019	SELL	$69.31 - $91.53 $415,236 - $548,356	-5,991 Closed	0 $0
Q4 2018 Jan 17, 2019	BUY	$68.32 - $124.36 $336,066 - $611,726	4,919 Added 458.86%	5,991 $427,000
Q3 2018 Nov 02, 2018	SELL	$98.88 - $125.85 $5,042 - $6,418	-51 Reduced 4.54%	1,072 $0
Q2 2018 Jul 24, 2018	BUY	$75.3 - $105.99 $73,191 - $103,022	972 Added 643.71%	1,123 $0
Q1 2018 May 03, 2018	BUY	$75.88 - $92.43 $1,441 - $1,756	19 Added 14.39%	151 $13,000
Q4 2017 Feb 02, 2018	BUY	$58.53 - $77.59 $3,336 - $4,422	57 Added 76.0%	132 $10,000
Q3 2017 Oct 20, 2017	BUY	$47.97 - $61.28 $3,597 - $4,596	75	75 $5,000

Others Institutions Holding NBIX

# of Institutions

649

Shares Held

97.1M

Call Options Held

749K

Put Options Held

553K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $11.9B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Meeder Asset Management Inc with notifications on news.

Account

Meeder Asset Management Inc Neurocrine Biosciences Inc Transaction History